{"id":"ros1","name":"ROS1","symbol":"ROS1","route":"/targets/ros1/","asOf":"2026-09-06","xrefs":[{"hgnc":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:10261","ensembl":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000047936","uniprot":"https://www.uniprot.org/uniprotkb/P08922/entry","alphafold-db":"https://alphafold.ebi.ac.uk/entry/P08922","chembl":"https://www.ebi.ac.uk/chembl/explore/target/CHEMBL5568","open-targets":"https://platform.opentargets.org/target/ENSG00000047936","civic":"https://civicdb.org/genes/6098/summary","oncokb":"https://www.oncokb.org/gene/ROS1","cosmic":"https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=ROS1","cbioportal":"https://www.cbioportal.org/results/mutations?cancer_study_list=msk_impact_2017&gene_list=ROS1","depmap":"https://depmap.org/portal/gene/ROS1?tab=overview","human-protein-atlas":"https://www.proteinatlas.org/ENSG00000047936-ROS1","ncbi-gene":"https://www.ncbi.nlm.nih.gov/gene/6098","omim":"https://www.omim.org/entry/165020"}],"products":[{"id":"crizotinib","name":"Crizotinib","status":"approved","modality":"Small-molecule ALK/ROS1/MET TKI (first generation)","route":"/drugs/crizotinib/"},{"id":"entrectinib","name":"Entrectinib","status":"approved","modality":"Small-molecule TRK/ROS1/ALK TKI (CNS-penetrant)","route":"/drugs/entrectinib/"},{"id":"iruplinalkib","name":"Iruplinalkib","status":"approved","modality":"Oral ALK and ROS1 tyrosine kinase inhibitor","route":"/drugs/iruplinalkib/"},{"id":"oncomine-dx-target-test","name":"Oncomine Dx Target Test","status":"approved","modality":"Tissue NGS companion diagnostic test (multi-gene panel)","route":"/drugs/oncomine-dx-target-test/"},{"id":"repotrectinib","name":"Repotrectinib","status":"approved","modality":"Small-molecule kinase inhibitor (ROS1 / NTRK)","route":"/drugs/repotrectinib/"},{"id":"taletrectinib","name":"Taletrectinib","status":"approved","modality":"Small-molecule ROS1 TKI (next generation, CNS-penetrant)","route":"/drugs/taletrectinib/"}],"trials":[{"id":"nct02767804","name":"eXalt3","nct":"NCT02767804","phase":"3","status":"positive"},{"id":"alesia","name":"ALESIA","nct":"NCT02838420","phase":"3","status":"positive"},{"id":"alta-1l","name":"ALTA-1L","nct":"NCT02737501","phase":"3","status":"positive"},{"id":"alex","name":"ALEX","nct":"NCT02075840","phase":"3","status":"positive"},{"id":"j-alex","name":"J-ALEX","phase":"3","status":"positive"},{"id":"profile-1014","name":"PROFILE 1014","nct":"NCT01154140","phase":"3","status":"positive"},{"id":"nct06564324","name":"A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients","nct":"NCT06564324","phase":"3","status":"recruiting"},{"id":"nct05170204","name":"A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small C","nct":"NCT05170204","phase":"3","status":"active"},{"id":"nct06140836","name":"A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)","nct":"NCT06140836","phase":"3","status":"active"},{"id":"nct04603807","name":"A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) Metastases","nct":"NCT04603807","phase":"3","status":"active"},{"id":"nct07154706","name":"Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)","nct":"NCT07154706","phase":"3","status":"recruiting"},{"id":"nct04632758","name":"Study Comparing WX-0593 to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients","nct":"NCT04632758","phase":"3"},{"id":"nct05987332","name":"IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma","nct":"NCT05987332","phase":"2/3","status":"active"},{"id":"nci-match","name":"NCI-MATCH (EAY131)","nct":"NCT02465060","phase":"platform","status":"active"},{"id":"alchemist","name":"ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials)","nct":"NCT02194738","phase":"platform","status":"active"},{"id":"determine-trial","name":"DETERMINE","nct":"NCT05722886","phase":"platform","status":"recruiting"},{"id":"cupisco","name":"CUPISCO","nct":"NCT03498521","phase":"2","status":"positive"},{"id":"papmet","name":"PAPMET (SWOG S1500)","nct":"NCT02761057","phase":"2","status":"positive"},{"id":"geometry-mono-1","name":"GEOMETRY mono-1","nct":"NCT02414139","phase":"2","status":"positive"},{"id":"national-lung-matrix-trial","name":"National Lung Matrix Trial","nct":"NCT02664935","phase":"2","status":"completed"},{"id":"tapur","name":"TAPUR (Targeted Agent and Profiling Utilization Registry)","nct":"NCT02693535","phase":"2","status":"recruiting"},{"id":"nct04641754","name":"A Study Evaluates the Safety and Efficacy of WX-0593 in ALK -Positive, or ROS1-positive Non-small Cell Lung Cancer","nct":"NCT04641754","phase":"2"},{"id":"nct04302025","name":"A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)","nct":"NCT04302025","phase":"2","status":"recruiting"},{"id":"nct02568267","name":"Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangeme","nct":"NCT02568267","phase":"2","status":"active"},{"id":"nct05765877","name":"Neoadjuvant WX-0593 in Resectable ALK-positive or ROS1-positive Non-small Cell Lung Cancer","nct":"NCT05765877","phase":"2","status":"recruiting"},{"id":"nct06315010","name":"Repotrectinib in ROS1-positive Non-small Cell Lung Cancer Patients With Active Brain Metastasis","nct":"NCT06315010","phase":"2","status":"recruiting"},{"id":"nct05725200","name":"Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer","nct":"NCT05725200","phase":"2","status":"recruiting"},{"id":"nct04919811","name":"Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC","nct":"NCT04919811","phase":"2","status":"active"},{"id":"nct04589845","name":"Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study","nct":"NCT04589845","phase":"2","status":"active"},{"id":"nct03093116","name":"A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements","nct":"NCT03093116","phase":"1/2","status":"recruiting"},{"id":"nct04094610","name":"A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations","nct":"NCT04094610","phase":"1/2","status":"recruiting"},{"id":"nct02650401","name":"Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options","nct":"NCT02650401","phase":"1/2","status":"active"},{"id":"nct03947385","name":"Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions","nct":"NCT03947385","phase":"1/2","status":"recruiting"},{"id":"profile-1001-ros1","name":"PROFILE 1001 ROS1 expansion cohort","nct":"NCT00585195","phase":"1","status":"positive"}],"pathways":[],"companies":["bms","innovent","nuvation-bio","pfizer","qilu-pharmaceutical","roche-genentech","thermo-fisher"],"keyPapers":["paper-shaw-crown-lorlatinib-crizotinib-nejm-2020","paper-shaw-alk-resistance-mutations-lorlatinib-jco-2019","paper-aggarwal-plasma-genotyping-personalised-therapy-jama-oncol-2019","paper-leighl-nile-cfdna-tissue-genotyping-ccr-2019","paper-lindeman-lung-molecular-testing-guideline-jto-2018","paper-jordan-prospective-lung-adenocarcinoma-msk-cancer-discov-2017","paper-bergethon-ros1-rearrangements-lung-jco-2012"],"hotspots":[{"label":"G2032R (solvent front)","position":2032,"kind":"resistance","frequency":"The most common ROS1 resistance mutation after crizotinib","drugs":["repotrectinib","taletrectinib"]},{"label":"L2026M (gatekeeper) and D2033N, S1986F/Y","position":2026,"kind":"resistance","drugs":["repotrectinib","taletrectinib"]}],"openQuestions":[],"assays":[{"id":"oncomine-dx","name":"Oncomine Dx Target Test","cutoff":"Per companion claim: BRAF V600E (dabrafenib plus trametinib), ROS1 fusions (crizotinib), EGFR (gefitinib), RET fusions (pralsetinib), MET exon 14 (tepotinib), EGFR exon 20 insertions"}],"resistance":[],"licence":"CC BY-NC 4.0, attribution to OnCo (https://onco.cc); commercial use needs a licence"}